Yanzhong Wang
Papers
1
Total Citations
12
H-Index
1
About
Yanzhong Wang is a leading clinical researcher whose work sits at the intersection of ophthalmology and radiation oncology, with a primary focus on neovascular age-related macular degeneration (nAMD)—a leading cause of blindness worldwide. His most significant contribution is the landmark STAR trial, a pivotal, randomised, double-masked, sham-controlled device study investigating stereotactic radiotherapy as a novel treatment for nAMD. This work addresses a critical unmet need: reducing the burden of frequent anti-VEGF injections, the current first-line therapy. By demonstrating that ionising radiation can mitigate key pathogenic processes underlying nAMD, Wang's research offers a potential paradigm shift in disease management, aiming to preserve vision with fewer interventions. The STAR trial, published in 2024, has already garnered 12 citations, reflecting its immediate impact on the field. Wang’s work is notable for its rigorous, sham-controlled design, setting a high standard for device trials in ophthalmology. For students and researchers, his research exemplifies how cross-disciplinary approaches—combining radiotherapy with retinal biology—can pioneer new therapeutic pathways for chronic, blinding diseases.
Research Focus
Key Achievements
Top Papers
- 1